Targeted radionuclide therapy and diagnostic imaging of SSTR positive neuroendocrine tumors: a clinical update in the new decade
Neuroendocrine tumors (NETs) are a heterogeneous group of neoplasms characterized by their overexpression of somatostatin receptors (SSTRs), which can be utilized for peptide receptor radionuclide therapy. This review provides a comprehensive update on the clinical trials of radiolabeled SSTR-target...
Saved in:
| Main Authors: | Katherine N. Haugh, Alexis M. Sanwick, Ivis F. Chaple |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-08-01
|
| Series: | Frontiers in Nuclear Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fnume.2025.1655419/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Peptide receptor radionuclide therapy for ectopic Cushing’s syndrome caused by metastatic neuroendocrine neoplasms
by: Emma Boehm, et al.
Published: (2024-11-01) -
177Lu-DOTATATE peptide receptor radionuclide therapy in metastatic or advanced and inoperable primary neuroendocrine tumors of rare sites
by: Pradeep Thapa, et al.
Published: (2017-07-01) -
Development of a methodology for the analysis of radionuclide impurities in radiopharmaceuticals by gamma-ray spectrometry
by: Eduardo Bonfim De Paula, et al.
Published: (2017-11-01) -
Peptide receptor radionuclide therapy with 177Lu-DOTATATE for metastatic neuroendocrine tumor occurring in association with multiple endocrine neoplasia type 1 and cushing's syndrome
by: Chinna Naik, et al.
Published: (2017-04-01) -
Unmasking insulinoma following commencement of somatostatin analogues in malignant neuroendocrine tumours
by: Isuru Gamage, et al.
Published: (2025-07-01)